MARKET $65B AFRICAN PHARMA BY 2030 TARGET 40M SMARTPHONE USERS — PHASE 1 COUNTERFEIT RATE 16.7% OF REGIONAL SUPPLY ADHERENCE TARGET 50%→75% ERROR REDUCTION TARGET 40% UN SDG 3 · 8 · 9 ALIGNED MARKET $65B AFRICAN PHARMA BY 2030 TARGET 40M SMARTPHONE USERS — PHASE 1 COUNTERFEIT RATE 16.7% OF REGIONAL SUPPLY ADHERENCE TARGET 50%→75% ERROR REDUCTION TARGET 40% UN SDG 3 · 8 · 9 ALIGNED

Medication safety
infrastructure for a
$65B market.

70%
meds bought without
consultation
16.7%
of regional drug
supply counterfeit
1:10,000
pharmacist-to-patient
ratio, rural Nigeria
Specimen Verification Live Model
Sample
Amoxicillin 500mg
Trust Score
98.4
Hologram
Matched
Batch Code
Verified
Guidance (Yoruba)

"Mu oogun yi pelu ounje. Pari gbogbo ọjọ meje lati dena atako oogun."

Take with food. Complete the full 7-day course to prevent resistance.

Illustrative model output — see live interactive demo →

The Opportunity

An unaddressed market,
not just an unmet need.

Existing solutions have failed to scale because they don't address the last mile of patient decision-making in low-resource, low-connectivity environments — leaving a structural gap worth closing.

Consultation Deficit
70%
of medications purchased without professional consultation

Patients default to informal vendors with limited clinical training — a trust vacuum with no incumbent solving it at scale.

Counterfeit Exposure
16.7%
of the regional drug supply is counterfeit or substandard

Roughly one in six drugs in circulation. These fuel antimicrobial resistance and drive preventable mortality.

Human-Resource Gap
1:10,000
pharmacist-to-patient ratio in rural Nigeria

A structural scarcity that no headcount-based intervention can close — but software can.

Why Now

Smartphone penetration across Sub-Saharan Africa has crossed the threshold needed to deliver software-based clinical guidance directly to the point of consumption — for the first time, at population scale.

$65B
addressable African pharmaceutical market by 2030
The Solution

Middleware that sits between patient and pharmacy.

Four integrated capabilities transform any smartphone into a verified, multilingual point of medication intelligence — engineered for the connectivity realities of the region it serves.

SDG 3 Good Health & Well-being

Counterfeit Shield

Computer-vision scanning analyzes holograms, serial numbers, and packaging security features against a proprietary manufacturer-verified database. Trust Score returned in seconds.

Local-Language NLP

Dosage instructions and side-effect warnings delivered in Yoruba, Hausa, Igbo, and Pidgin — clinical guidance that's actually understood, not just translated.

Offline-First Architecture

"Sync-and-Save" keeps interaction databases, adherence schedules, and core guidance fully functional without cellular connectivity — built for where it will actually be used.

Adherence Guardian

Real-time drug-drug and drug-food interaction alerts, plus smart nudges to complete antibiotic courses — protecting individual patients and slowing antimicrobial resistance.

Business Model

Three revenue streams. One impact-aligned engine.

RxLoop is free at the point of basic use — the business model monetizes the institutions and data layers built on top of population-scale trust, not the patient's access to safety.

Stream 01 · B2B SaaS

Pharmaceutical Partnerships

Licensed pharmacies, hospital groups, and clinic networks subscribe to dashboards with real-time visibility into patient adherence, medication history, and population-level insights.

Monthly subscription · justified by improved retention & outcomes
Stream 02 · Marketplace

Telemedicine Consultations

Core AI guidance stays free. Users can escalate instantly to licensed pharmacists for video or audio consultations at a transparent flat fee — high-margin, on-demand revenue.

Flat consultation fee · creates pharmacist gig-economy income
Stream 03 · Data Licensing

Aggregate Insights

Anonymized, aggregated data on drug usage patterns, counterfeit hotspots, and adherence behaviors licensed to NGOs, ministries of health, and global health organizations.

Data-for-impact licensing · aligns incentives toward public good
Value Proposition
  • For patients: free, trustworthy verification and guidance at the exact moment of decision — no clinic visit required.
  • For pharmacies: a retention and outcomes layer that turns foot traffic into adherence data and recurring relationships.
  • For funders: a measurable, reportable public-health outcome engine — adherence, error reduction, and AMR mitigation, at population scale.
Why the Model Scales

Free-to-patient access removes the only friction that matters at the last mile — willingness to use the product at all. Every additional user makes the counterfeit-detection database, the language models, and the population-health data more valuable to the institutions paying for it. Growth on one side of the platform compounds revenue on the other.

Technology Stack
Detection Layer

Computer-vision models trained on manufacturer packaging, holograms, and batch-code databases.

Guidance Layer

NLP models fine-tuned for Yoruba, Hausa, Igbo, and Pidgin clinical communication.

Resilience Layer

Offline-first "Sync-and-Save" data architecture for low-connectivity environments.

Distribution Layer

Lightweight mobile client designed for low-spec Android devices at minimal data cost.

Measurable Outcomes

Built for reportable impact, not vanity metrics.

Adherence
5075
Regional avg → Target rate
Error Reduction
40%
Drug-interaction errors avoided
Scale
40M
Smartphone users, initial target
AMR Combat
100%
Course-completion education coverage
For Partners

Pharmacies, NGOs & Health Systems

Subscribe to adherence dashboards, license aggregate population-health data, or integrate RxLoop's verification layer into your existing distribution network.

Discuss a partnership
For Patients

A Digital Pharmacist in Every Pocket

Free guidance in your language, instant counterfeit checks before you take a single pill, and reminders that help you finish every course safely.

See the demo
Execution

Roadmap to 2030

A deliberate, phased approach to building sustainable pharmaceutical infrastructure across the continent.

PHASE 01 · 2026–2027

Nigeria Pilot

Launch in Lagos urban hubs and select rural clusters in Northern Nigeria. Focus on 40 million smartphone users. Deep NLP training for major local languages.

Target: 250,000 active users in Year 1
PHASE 02 · 2028–2029

West African Expansion

Scale to Ghana and Côte d'Ivoire. Adapt NLP models for additional dialects. Strengthen B2B partnerships with regional pharmacy chains and health systems.

Target: 2.5M+ users across three countries
PHASE 03 · 2030+

Continental Integration

Pan-African rollout. Capture meaningful share of the $65 billion African pharmaceutical market. Become the default layer of medication-safety infrastructure.

Target: 25M+ users
Global Alignment

Built for grant and impact-capital eligibility.

RxLoop is strategically positioned to attract impact-focused capital from the world's leading global-health and innovation funders.

UN Sustainable Development Goals
SDG 3 — Good Health & Well-being SDG 8 — Decent Work & Growth SDG 9 — Industry & Innovation
Strategic Funder Alignment

Resonates with the mandates of the Bill & Melinda Gates Foundation, Grand Challenges Canada, and the Tony Elumelu Foundation — organizations focused on scalable, culturally intelligent solutions that create both health impact and economic opportunity.

Leadership

Built by people who care deeply about the outcome.

NF
CO-FOUNDER

Nathaniel Friday

Co-Founder & Visionary

Nathaniel co-founded RxLoop to close one of healthcare's most dangerous gaps: the moment between receiving a prescription and safely completing treatment. He believes frontier AI, when built with cultural intelligence and radical accessibility, can protect millions of lives across the continent.

NU
CO-FOUNDER

Nwosu Uzoma

Co-Founder

Nwosu co-founded RxLoop with a focus on building infrastructure that works for the realities of the communities it serves — from connectivity constraints to the languages patients actually speak at the point of care.

Coming Soon

See the platform.
Shape the pilot.

The Nigeria pilot launches in late 2026. Explore the interactive demo, then join the early-access list for investors, partners, and healthcare professionals shaping the rollout.